David Bautz
Research analyst, biotech, small-cap, medium-term horizon

Lipocine Is A Compelling Investment Opportunity With Impending Phase 3 Data

Lipocine (NASDAQ:LPCN) is a specialty pharmaceutical company that has an oral drug delivery technology for products that affect men's and women's health. The technology is designed to improve patient compliance and safety through orally available products, while at the same time increasing the bioavailability of drugs that are poorly absorbed through oral administration and do not reach a sufficient threshold in the circulation.

The company is currently developing three product candidates that are designed to enhance the pharmacokinetic parameters of the drugs, facilitate lower dosing requirements, reduce side effects, and limit gastrointestinal interactions that would otherwise decrease the effectiveness of the compounds.

Below we provide an overview of the two therapeutic areas that Lipocine is focused on, testosterone

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details